Insight

Daratumumab+ Lenalidomide vs Lenalidomide for Post-Transplant Maintenance in Multiple Myeloma

Amrita Krishnan

Nov 12, 2024, 17:56

Daratumumab+ Lenalidomide vs Lenalidomide for Post-Transplant Maintenance in Multiple Myeloma

Mike Thompson, Vice President of Clinical Partnerships at Tempus AI, shared a recent article by Amrita Krishnan on X:

“SWOG Cancer Research Network S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (mmMRD) to direct Therapy Duration (DRAMMATIC) by Dr. Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton and Robert Z. Orlowski.”

Multiple Myeloma

Title: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapying Patients with Multiple Myeloma (mm) Using Minimal Residual Disease To direct Therapy Duration (DRAMMATIC study): SWOG s1803

Authors: Amrita Krishnan, Antje Hoering, Parameswaran Hari, Rachael Sexton and Robert Z. Orlowski

Multiple Myeloma

More posts featuring Mike Thompson.

Amrita Krishnan Antje Hoering cancer DRAMMATIC Mike Thompson multiple myeloma OncoDaily Oncology Parameswaran Hari Rachael Sexton Robert Z. Orlowski SWOG Cancer Research Network

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

UICC and Zambia’s Ministry of Health Sign MoU to Improve Cancer Care

Special Coverage